Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of GT-220F that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

Question 4

What will my weekly visits involve during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

Question 5

How long will I need to participate in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

Question 6

What happens if I experience side effects while taking GT-220F?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) clinical trial (NCT06866795). Contact the study team or your healthcare provider for specific answers.

What this study is about